These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11573324)

  • 1. [A new generation of fluoroquinolones--new possibilities for the treatment of respiratory community-acquired infections].
    Iakovlev SV
    Antibiot Khimioter; 2001; 46(6):38-42. PubMed ID: 11573324
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of new quinolones in respiratory infections].
    Sanz Moreno J; Jiménez Rodríguez A
    Rev Clin Esp; 2000 Dec; 200(12):682-4. PubMed ID: 11234474
    [No Abstract]   [Full Text] [Related]  

  • 3. Newer fluoroquinolones and the management of respiratory tract infections.
    Karchmer AW
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S15. PubMed ID: 10984322
    [No Abstract]   [Full Text] [Related]  

  • 4. Respiratory fluoroquinolones: differences in the details.
    Mandell LA; Iannini PB; Tillotson GS
    Clin Infect Dis; 2004 May; 38(9):1331-2; author reply 1332-3. PubMed ID: 15127351
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of newer fluoroquinolones in lower respiratory tract infections.
    Lode H; Allewelt M
    J Antimicrob Chemother; 2002 May; 49(5):709-12. PubMed ID: 12003962
    [No Abstract]   [Full Text] [Related]  

  • 6. Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.
    Blondeau JM; Hansen GT
    Expert Opin Pharmacother; 2001 Feb; 2(2):317-35. PubMed ID: 11336589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.
    Blasi F; Tarsia P; Cosentini R; Cazzola M; Allegra L
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1165-77. PubMed ID: 12831351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the clinical efficacy and safety of injectable quinolones in the treatment of respiratory tract infections (discussion)].
    Kohno S; Watanabe A; Mikasa K; Asano K
    Jpn J Antibiot; 2003 Apr; 56(2):93-104. PubMed ID: 12825412
    [No Abstract]   [Full Text] [Related]  

  • 9. Expanding uses of fluoroquinolones: opportunities and challenges.
    Hooper DC
    Ann Intern Med; 1998 Dec; 129(11):908-10. PubMed ID: 9867736
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of newer fluoroquinolones in lower respiratory tract infections.
    Lode H; Allewelt M
    J Antimicrob Chemother; 2002 Jul; 50(1):151-4. PubMed ID: 12613473
    [No Abstract]   [Full Text] [Related]  

  • 11. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
    Momméja-Marin H; Carbon C
    Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bacteriology in community-acquired respiratory pathology].
    Weber P
    Presse Med; 1998 Mar; 27(11):546-8. PubMed ID: 9767971
    [No Abstract]   [Full Text] [Related]  

  • 13. [Community-acquired bacteremias of respiratory origin].
    Royo García G
    Rev Clin Esp; 1997 Dec; 197 Suppl 5():32-3. PubMed ID: 9558605
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.
    Doern GV
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):821-35. PubMed ID: 17140358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
    Calbo E; Garau J
    Respiration; 2005; 72(6):561-71. PubMed ID: 16354997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections.
    Bishai W
    Clin Ther; 2002 Jun; 24(6):838-50; discussion 837. PubMed ID: 12117077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New concepts in antimicrobial therapy for emergency department infections.
    Talan DA
    Ann Emerg Med; 1999 Oct; 34(4 Pt 1):503-16. PubMed ID: 10532910
    [No Abstract]   [Full Text] [Related]  

  • 18. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
    Appelbaum PC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
    Spivey IM
    Clin Pharm; 1993 Jun; 12(6):452-8. PubMed ID: 8403817
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical assessment of tosufloxacin tosilate.
    Kohno S
    J Infect Chemother; 2002 Mar; 8(1):19-27. PubMed ID: 11957115
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.